{"ticker": {"uuid": "f8a9ae80-a848-43e2-9ed4-62fd74bc88af", "symbol": "RLMD", "name": "Relmada Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "RELMADA THERAPEUTICS INC (RLMD) Stock Chart", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTFB1bEh5Y2NNbFRFY05zU0pDMFhCVkFHYnU2WWpkZTA5a0RzSlFjVy16clBYeDcxcUxlcVBfc2oxd2RMWVBrcVoxV2xJdVBpUWNXYnpFNjRmSnJGd3o1bmtoSG54a3M?oc=5", "source_name": "ChartMill", "published_at": "2026-07-11T00:00:02+00:00", "published_display": "11 Jul 2026 00:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho Securities Maintains Relmada Therapeutics(RLMD.US) With Buy Rating, Maintains Target Price $19", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPZmdvamZ2VlRHU1h0YWhndWd6VVh5eHNocW45dkxTazNZblJLQi1mWTFQMUlxUXZSTTlUT09lTHRHdnVjdHlPWkFjTnRhdTRqN2pnSVdrT1pCbjMwMmh1Mk9GV0c5NTBpMUYyYWZ5OEdMdGV6WU42YVZ1elRHd1JkMEpDTU9kcHQ1RzBuQ2NEZGxyYkVYZ1ZpX3FLcHppWmttSDZ6dUZBTFZ2YlJCMFVGYzlNZzNuY2pwRHpUUEVyTGQ?oc=5", "source_name": "Moomoo", "published_at": "2026-07-10T12:31:00+00:00", "published_display": "10 Jul 2026 12:31", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics (RLMD) Short Interest & Short Float | Updated Jul 2026", "summary": "Relmada Therapeutics (RLMD) saw a significant increase in short interest, with 10.65 million shares sold short as of June 30, 2026, marking a 75.70% rise from the previous report. The short interest ratio stands at 3.1 days to cover, and 11.87% of the public float is sold short. ", "url": "https://www.marketbeat.com/stocks/NASDAQ/RLMD/short-interest/", "source_name": "MarketBeat", "published_at": "2026-07-10T09:40:39", "published_display": "10 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RLMD - Relmada Therapeutics Inc Options", "summary": "This article provides a detailed financial overview of Relmada Therapeutics Inc (RLMD) options, including its last closing price, market capitalization, various financial ratios, and stock performance metrics. It lists key data points such as EPS, sales growth, insider/institutio", "url": "https://finviz.com/stock?t=RLMD&b=2&p=m&ty=oc&ov=list_strike&s=5", "source_name": "Finviz", "published_at": "2026-07-04T10:10:45", "published_display": "04 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Relmada Therapeutics, Inc. \u2013 NASDAQ:RLMD", "summary": "The article displays the \"Price to book forward\" metric for Relmada Therapeutics, Inc. (NASDAQ: RLMD). It provides the financial data for the company under this specific financial analysis category. The content is presented with a focus on financial information related to the sto", "url": "https://www.tradingview.com/symbols/NASDAQ-RLMD/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T06:40:10", "published_display": "30 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics Joins Russell 2000\u00ae and Russell 3000\u00ae Indexes", "summary": "Relmada Therapeutics, a clinical-stage biotechnology company, announced its inclusion in the Russell 2000\u00ae and Russell 3000\u00ae Indexes, effective after market close on June 26, 2026. This inclusion reflects the company's progress, including robust 12-month data for its NDV-01 candi", "url": "https://finance.yahoo.com/markets/stocks/articles/relmada-therapeutics-joins-russell-2000-110000111.html", "source_name": "Market source", "published_at": "2026-06-30T05:10:23", "published_display": "30 Jun 2026 05:10", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics Joins Russell 2000, Russell 3000 Indexes", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/relmada-therapeutics-joins-russell-2000-185518318.html", "source_name": "MT Newswires", "published_at": "2026-06-29T18:55:18+00:00", "published_display": "29 Jun 2026 18:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics, Inc.(NasdaqCM: RLMD) added to Russell 2500 Growth Benchmark", "summary": "Relmada Therapeutics, Inc. (NasdaqCM: RLMD) has been added to the Russell 2500 Growth Benchmark, reflecting a significant inclusion in key market indices. This follows several other recent inclusions in various Russell indices, including the Russell 2000, Russell 3000, and Russel", "url": "https://www.marketscreener.com/news/relmada-therapeutics-inc-nasdaqcm-rlmd-added-to-russell-2500-growth-benchmark-ce7f5fdfda81f121", "source_name": "marketscreener.com", "published_at": "2026-06-29T19:39:36", "published_display": "29 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada lands in Russell 2000 and Russell 3000 after reconstitution", "summary": "Relmada Therapeutics (Nasdaq: RLMD) announced its inclusion in the Russell 2000 and Russell 3000 indexes, effective after the U.S. market close on June 26, 2026. This addition, part of the Russell Indexes reconstitution, is a significant accomplishment reflecting the company's pr", "url": "https://www.stocktitan.net/news/RLMD/relmada-therapeutics-joins-russell-2000-and-russell-3000-wqppl77notsm.html", "source_name": "Stock Titan", "published_at": "2026-06-29T11:12:40", "published_display": "29 Jun 2026 11:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Relmada Therapeutics, Inc. \u2013 NASDAQ:RLMD", "summary": "The article focuses on the \"Price to earnings forward\" metric for Relmada Therapeutics, Inc. (NASDAQ: RLMD). It appears to be a financial data snippet from TradingView, indicating a specific financial valuation measure for the company. The content itself provides the context of w", "url": "https://www.tradingview.com/symbols/NASDAQ-RLMD/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T10:12:40", "published_display": "29 Jun 2026 10:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics, Inc.(NasdaqCM: RLMD) added to Russell 2500 Index", "summary": "Relmada Therapeutics, Inc. (NasdaqCM:RLMD), a clinical-stage biotechnology company specializing in CNS and metabolic disorders, has been added to the Russell 2500 Index. This inclusion follows several other recent additions to various Russell indexes, including the Russell Small ", "url": "https://www.marketscreener.com/news/relmada-therapeutics-inc-nasdaqcm-rlmd-added-to-russell-2500-index-ce7f5fdfd188f324?utm_source=copy&utm_medium=social&utm_campaign=share", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T05:10:23", "published_display": "29 Jun 2026 05:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RLMD: Next-Generation Bladder Cancer Therapy Platform Will Drive Future Upside Potential", "summary": "The fair value estimate for Relmada Therapeutics (RLMD) has increased to $12.67, driven by a new analyst target and the perceived differentiation of its NDV-01 platform for bladder cancer therapy. The company has also increased its authorized common stock and was added to the S&P", "url": "https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-rlmd/relmada-therapeutics/ksrf7qxl-bladder-cancer-and-compulsive-disorder-therapies-will-support-a-stronger-long-term-outlook/updates/2-the-analyst-price-target-for-relmada-therapeutics-has-shifte", "source_name": "Simply Wall Street", "published_at": "2026-06-27T04:09:30", "published_display": "27 Jun 2026 04:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RLMD Jumps As HC Wainwright Launches Buy Coverage", "summary": "Relmada Therapeutics Inc. (RLMD) saw its stock jump by 3.72% after H.C. Wainwright initiated coverage with a Buy rating and a $12 price target, driven by optimism for its NDV-01 clinical trial. Despite current negative earnings and heavy R&D burn, the company maintains a strong b", "url": "https://www.timothysykes.com/news/relmadatherapeuticsinc-rlmd-news-2026_06_26-2/", "source_name": "Timothy Sykes", "published_at": "2026-06-26T20:38:00", "published_display": "26 Jun 2026 20:38", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics Inc Actuals & Estimates (NASDAQ:RLMD)", "summary": "This article provides an overview of Relmada Therapeutics, Inc. (NASDAQ: RLMD) stock, including its current price, market capitalization, and analyst forecasts. It details historical performance, future earnings estimates, and answers frequently asked questions regarding its fina", "url": "https://www.tradingview.com/symbols/NASDAQ-RLMD/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:40:35", "published_display": "26 Jun 2026 07:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RLMD Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "Relmada Therapeutics, Inc. (RLMD) has a one-year price target of $12.67 based on 6 analyst forecasts. Analysts predict a maximum price of $19.00 and a minimum of $9.00 for RLMD. The company's stock has seen a significant increase of 1190% over the last year, despite recent weekly", "url": "https://www.tradingview.com/symbols/NASDAQ-RLMD/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T05:39:55", "published_display": "26 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Millennium Group reports 4.57M Relmada shares (NASDAQ: RLMD) in 13G", "summary": "Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have reported shared voting and dispositive power over 4,567,952 shares of Relmada Therapeutics (NASDAQ: RLMD), representing 4.4% of the common stock. This Schedule 13G filing indicates that the r", "url": "https://www.stocktitan.net/sec-filings/RLMD/schedule-13g-relmada-therapeutics-inc-passive-investment-disclosure-5-c17743bef71e.html", "source_name": "Stock Titan", "published_at": "2026-06-23T21:10:21", "published_display": "23 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics stock maintained at Buy by H.C. Wainwright", "summary": "H.C. Wainwright has reiterated a Buy rating and a $12.00 price target for Relmada Therapeutics Inc (NASDAQ:RLMD), highlighting the company's strong financial position and promising clinical pipeline for its NDV-01 program. Despite a recent net loss that slightly missed analyst fo", "url": "https://www.investing.com/news/analyst-ratings/relmada-therapeutics-stock-maintained-at-buy-by-hc-wainwright-93CH-4755239", "source_name": "Investing.com", "published_at": "2026-06-23T12:12:14", "published_display": "23 Jun 2026 12:12", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains Relmada Therapeutics(RLMD.US) With Buy Rating, Maintains Target Price $12", "summary": "H.C. Wainwright has reaffirmed its Buy rating for Relmada Therapeutics (RLMD.US) and maintained its target price of $12. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/71891923/hc-wainwright-maintains-relmada-therapeutics-rlmdus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-23T11:40:10", "published_display": "23 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Reiterates Buy Rating on Relmada Therapeutics Inc (RLMD)", "summary": "H.C. Wainwright analyst Andres Maldonado has reiterated a Buy rating on Relmada Therapeutics Inc (RLMD) with a $12.00 price target. The article, published on June 23, 2026, is a premium content piece and requires a subscription to StreetInsider.com for full access.", "url": "https://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Relmada+Therapeutics+Inc+%28RLMD%29/26675565.html", "source_name": "StreetInsider", "published_at": "2026-06-23T11:12:14", "published_display": "23 Jun 2026 11:12", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13G Relmada Therapeutics For: 22 June By Investing.com", "summary": "This article reports on a Form 13G filing for Relmada Therapeutics, dated June 22. It mentions the stock symbol RLMD and includes minor fluctuations in various global indices and commodities. The primary content of the article is the announcement of the Form 13G filing itself, wi", "url": "https://ng.investing.com/news/stock-market-news/form-13g-relmada-therapeutics-for-22-june-93CH-2568939", "source_name": "Investing.com Nigeria", "published_at": "2026-06-23T01:40:10", "published_display": "23 Jun 2026 01:40", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics, Inc.(NasdaqCM:RLMD) added to S&P Pharmaceuticals Select Industry Index", "summary": "Relmada Therapeutics, Inc. (NasdaqCM:RLMD) has been added to the S&P Pharmaceuticals Select Industry Index. The company is a clinical-stage biotechnology firm focused on developing therapies for central nervous system (CNS) and metabolic disorders, with its lead product candidate", "url": "https://www.marketscreener.com/news/relmada-therapeutics-inc-nasdaqcm-rlmd-added-to-s-p-pharmaceuticals-select-industry-index-ce7f5cd3d88df72c", "source_name": "marketscreener.com", "published_at": "2026-06-22T13:09:50", "published_display": "22 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 78, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics Inc (RLMD) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Relmada Therapeutics Inc (RLMD), noting its current risk score of 1.94, ranking 255 out of 389 in the Biotechnology & Medical Research industry. The company's beta is 0.40, indicating lower volatility relative to the S&P 500. The assess", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rlmd/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-19T08:39:59", "published_display": "19 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics (RLMD): 10 Best Growth Stocks Under $30 to Buy Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOc2lmUHFjQlhWTmVtRDZaVnJaVkViU2tzTEtPcmp5c1ZDdUJxTk8yOTZlZ0VPYUhPdTdqeVRkMFlBUndwQkhqczRzeGFYc2JaZXoyQ3pWUWF5Sm9RdTZwX0JTMWlzOWo2QmdWZ0cyckFsTGJZVVdHQzlhcWp0SmpXWW5qQ0o1UFY0UngtYmtrY3VsamEwblNNa0hB?oc=5", "source_name": "Market source", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada: NDV-01 Entering Phase 3 In NMIBC, But There's No Rush To Buy Stock Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWk0tUnBlNzAyVGdYRW1mMmRnMENaTEZQeVpwcnZFVFdackRzQWI0bkhFVno0S3ZSZnVsSVZmYVo5bHQzT3dZaTBIY3pCdE0yRHZ6VVdlczBMQUtITHBQeXJpLWstdVJhbEkwbHVKamt0SkcteXljcVZmYzFVd2ZveENBVjJQOTk2VG1PU0ZCczBOa1ZEUlVPeVFtd1R3UGR1b3lTVEd0Z3NETEJN?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RLMD News | RELMADA THERAPEUTICS INC (NASDAQ:RLMD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTE5oWENYWllaMVNjSTJqTjNMNzIwdHVIVktVMjZJcmo4VHBRa0w3aFJpWEZQa0hSOVpNV1BvTDdmdHNBZ0RsWlBNTURhSHBiSU1TRXhWaklHRjhRcEk?oc=5", "source_name": "ChartMill", "published_at": "2026-06-19T00:27:17+00:00", "published_display": "19 Jun 2026 00:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Initiates Relmada Therapeutics(RLMD.US) With Buy Rating, Announces Target Price $12", "summary": "H.C. Wainwright has initiated coverage on Relmada Therapeutics (RLMD.US) with a Buy rating. The firm has set a target price of $12 for the company's stock.", "url": "https://www.moomoo.com/news/post/71726864/hc-wainwright-initiates-relmada-therapeutics-rlmdus-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-06-19T00:40:23", "published_display": "19 Jun 2026 00:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HC Wainwright Initiates Relmada Therapeutics at Buy With $12 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/hc-wainwright-initiates-relmada-therapeutics-104623782.html", "source_name": "MT Newswires", "published_at": "2026-06-18T10:46:23+00:00", "published_display": "18 Jun 2026 10:46", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RLMD Initiates Coverage On by HC Wainwright & Co. -- Rating Set to Buy", "summary": "HC Wainwright & Co. initiated coverage on Relmada Therapeutics (RLMD) with a 'Buy' rating and a $12.00 target price. Despite a low GF Score\u2122 of 30/100 due to profitability and growth concerns, the company exhibits strong financial health. Analysts are confident in RLMD's potentia", "url": "https://www.gurufocus.com/news/8922324/rlmd-initiates-coverage-on-by-hc-wainwright-co-rating-set-to-buy", "source_name": "GuruFocus", "published_at": "2026-06-18T11:39:34", "published_display": "18 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright initiates Relmada stock coverage with buy rating", "summary": "H.C. Wainwright has initiated coverage on Relmada Therapeutics Inc (NASDAQ:RLMD) with a Buy rating and a $12 price target, citing its promising NDV-01 for non-muscle invasive bladder cancer. The stock has seen an impressive 843% one-year return, despite the company currently bein", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-initiates-relmada-stock-coverage-with-buy-rating-93CH-4749423", "source_name": "Investing.com", "published_at": "2026-06-18T11:08:09", "published_display": "18 Jun 2026 11:08", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Starts Relmada Therapeutics Inc (RLMD) at Buy, PT $12", "summary": "H.C. Wainwright analyst Andres Maldonado has initiated coverage on Relmada Therapeutics Inc (NASDAQ: RLMD) with a Buy rating. The firm has set a price target of $12 for the stock. This news indicates a positive outlook from H.C. Wainwright on the pharmaceutical company.", "url": "https://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Starts+Relmada+Therapeutics+Inc+%28RLMD%29+at+Buy%2C+PT+%2412/26662122.html", "source_name": "StreetInsider", "published_at": "2026-06-18T05:59:00", "published_display": "18 Jun 2026 05:59", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics Inc (RLMD) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Relmada Therapeutics Inc (RLMD), identifying its major shareholders and institutional holdings. It provides a breakdown of shareholder types, institutional shareholding trends over several quarters, and recent shareholder activity", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rlmd/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T21:09:45", "published_display": "17 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics Inc (RLMD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey focuses on the revenue breakdown of Relmada Therapeutics Inc (RLMD). It notes that relevant data regarding the company's business segments, regional revenue, and profit contribution have not yet been disclosed by Relmada Therapeutics Inc. The page pri", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rlmd/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T20:09:44", "published_display": "17 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10 Best Growth Stocks Under $30 to Buy Now", "summary": "This article identifies Relmada Therapeutics Inc. (NASDAQ:RLMD) as one of the best growth stocks under $30, highlighting its strong financial position and promising clinical pipeline. The company recently reported positive Phase 2 data for NDV-01, is well-capitalized to fund oper", "url": "https://www.insidermonkey.com/blog/10-best-growth-stocks-under-30-to-buy-now-1782530/4/", "source_name": "Insider Monkey", "published_at": "2026-06-17T11:19:09", "published_display": "17 Jun 2026 11:19", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics Inc (RLMD) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Relmada Therapeutics Inc (RLMD), noting its current valuation score of 7.88 within the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -6.02 and indicates that relevant data for P/B, P/S, and P/CF r", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rlmd/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-16T23:39:34", "published_display": "16 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics Inc (RLMD) Institutional Confidence", "summary": "Relmada Therapeutics Inc (RLMD) has an institutional shareholding score of 5.00, placing it 133rd in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 56.47%, a significant quarter-over-quarter increase of 184.86%. Steven Cohen is ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rlmd/sentiment", "source_name": "TradingKey", "published_at": "2026-06-15T22:39:58", "published_display": "15 Jun 2026 22:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics bolsters Sepranolone Program with Michael Quirk as Senior Advisor", "summary": "Relmada Therapeutics has appointed Michael Quirk as Senior Advisor for its Sepranolone Program, aiming to advance its central nervous system drug development. Dr. Quirk, a neuroscience veteran from Sage Therapeutics and AstraZeneca, brings over 20 years of experience in CNS trans", "url": "https://www.indianpharmapost.com/people/relmada-therapeutics-bolsters-sepranolone-program-with-michael-quirk-as-senior-advisor-20596", "source_name": "Indian Pharma Post", "published_at": "2026-06-13T08:38:57", "published_display": "13 Jun 2026 08:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/relmada-therapeutics-appoints-cns-drug-110000301.html", "source_name": "GlobeNewswire", "published_at": "2026-06-11T11:00:00+00:00", "published_display": "11 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/relmada-therapeutics-present-jefferies-global-110000984.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T11:00:00+00:00", "published_display": "28 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Relmada Therapeutics Inc (RLMD) Q1 2026 Earnings Call Highlights: Strong Financial Position and ...", "summary": "", "url": "https://finance.yahoo.com/news/relmada-therapeutics-inc-rlmd-q1-050201950.html", "source_name": "GuruFocus.com", "published_at": "2026-05-13T05:02:01+00:00", "published_display": "13 May 2026 05:02", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics Q1 Loss per Share Narrows", "summary": "", "url": "https://finance.yahoo.com/news/relmada-therapeutics-q1-loss-per-203559813.html", "source_name": "MT Newswires", "published_at": "2026-05-12T20:35:59+00:00", "published_display": "12 May 2026 20:35", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPWVFQZXhLNzNORGl4ZFdtc0xxd0pnekFYemIydldWc21EUWFrVFExX2FzYy1wVkY2V1ZPa2tlQVoxcFNCVEVLOFJLRmRjdHp2U1lVeDV5ZkFrXzlUVUxpMkFsUXB0VDlRX19kTWR1Ujc4LWVzQjBMNlJJMnNXLW0yVXhkTjdjT0lad0pMdFZUbGUyM0hpVFg3Nk83SkpsRU94NkZZTmw4SFVEdGZxS3c?oc=5", "source_name": "TradingView", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxPNDREOVlWclVTeUYtREpEcTUzTzNlMGkwRlhrbzBvTjA3QTN4TnZHN1UyODFZUFdCTUh6Yk5rTFFYNTFWR2Z4TDhXTnFrenN2WXFmNUxaR3JoZFZSNlIzazVGcEtLZVVWdHZiM2d0cEo5eDlnZmJFTEVKR0MtVldwRVlxVXVHc1YzOXlKeUNYRWtsTXFpaHR4M1BVX3ZITGk4Z1hCRzJyMmJOZDFBVnRwYWZjZ1p3SDYxYi0tZENncnBua2lOcDJrVmt1cXQtMWluTmdhQ1puZHVUdjhNNjVQQkt6OTlZLVpKeHNiS3FSMlIyMDBMVzlrUzVn?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotech Relmada will discuss Q1 results and business update May 12", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOOTJRQVpnVjV2WlMxdkxpQ19XNmFLd0hWWUk2TTRxenhnNXRqWnptdGNhNGxyZklobmdrU0RSbHZjbnBjWGxEaW1PNVlnZ3A5WUUtRnVWaDBsamFmbGhPZ1lva1Y5VzN2dHFQcDgzNnFRS1pZcXdPNEJfbG5uWVNXX1FPRkwtM3JmenN0OUxJelFNTkRhSjh0aE5ZMklNcHhBTmNyeDdJSkV1NlAwanBPN0JrcWhwZDR1eGNkMUNWQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Does Relmada Therapeutics (RLMD) Have the Potential to Rally 75.58% as Wall Street Analysts Expect?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNYWdLdG5pQUtrQW1mUHF1ODRSWFJTS2JTOTNxU0NveGtvM2drazdxYTJHcDBoanVKUTlGeTRYOE5vTWFHUVBLSjVzWU5qWEx2a1R1Ykc1N2JNMVFJdEpjYkJtRklQLTlDUXVIejJCWDd3SldPWTgtcFpRbkdYUy13TkpDUi0wVDFIVXF4ZGZBRlNJSG41Y3hkMWNKV2E4Q0NwejkxNDB5Qk42UURaYTg4?oc=5", "source_name": "qz.com", "published_at": "2026-04-22T22:35:53+00:00", "published_display": "22 Apr 2026 22:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAJBVV95cUxObmp0dXNWNW9Ub2lLMkEyUWpvbzJQMzhMRGhyV1lMb281clFDa0FZcXBKSEk4d01qcmY4QVdZV3gyNEd1RFNPR204eVJWeFBTeEVmNjg2MG1NMzlKV2JINmltWGhGM0RXSVV1czhDVWtZNXhlRmZZZTBIVVZGTGdkZktYdHdkZWlHalFjc1g1OFYySUJIcnNyeGktbG9tMWJ1V1k2NnZBV1VDbVZMNkhLa0VidTQxZEFLUXJmdUdLc3hvdkFjcmtGN19Oa3pqMmY1aEZvOXhQSzZvUnRNbmJpMUZOM3FYZjd0TXAtNzBBVFVfLVlZMUoxbzVGOHFGVE81S2t2bENhRHlQbzNZdDNZd2dLWFZKN1EtczBlYnZCX291VjdTbG9GVTJ1LTY?oc=5", "source_name": "TradingView", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics: 2 New Assets, 2 New 'Blockbusters'? I'd Wait And See (NASDAQ:RLMD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPdHhNY2FMMjd6dGpyb2M1Q0kyMkgtOXhFYkNWQ1M4ZVhfVlpmY2sxcHh3V2NLcU1wZ21Pci1xUVo5Sm1qc1dhTGs0SllUejRqcDJuS3JzTG5OMFlGV2g5WjZTUThmMWtmblJMV2lrQl9vX2JEUmlhVnRkSVE0UHZvenUzM3A3OHRkYzNhRDBRN2VzQk95aHh3eEU2alBOci1rbWIyN3ZPVmdpa25tNGc?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Here\u2019s What Makes Mizuho Bullish on Relmada Therapeutics Inc (RLMD) Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQbEYtWlY0RnkzbE5rbjEzNTlXRS0tZUs3Y2twWlljYy16RGw5OFpnLWFDU0lKWHhmamZqN0d6aDRKWUN2UWd4VHFZU0lqZHdFUEdDWTMyc0VheHo2VnliTjVfNXktQVo0THBDTUNmQkdya1dOeVlURHJ3d1BWWXIyblBlUHRfWVBxTXdHY0VPclRNTnZ1dmExZUJleVB6WkZJWG80VVhXR1hfQQ?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada wins bullish view at Piper Sandler on cancer therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxNLWR5WmFILUtTTVVOaWJMc19zQjFOWW5KZVp2T0R5Wm5VSzltaVFnbjRNbmtYM083N0JkckdoRHdrS0hBZ0xZSWxmZ1lrdlVja1NMNk01Q2Y4dGF5SGRHaUd4MERsRkRjX0tUSUF2TFRHM1g2QUZWQ0ZsYlFBdnZnZVZTcTQ5bEpoeHJN?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Relmada Therapeutics (RLMD) Valuation After NDV\u201101 Phase 2 Bladder Cancer Data", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Relmada secures $160M private raise for drug R&D and operations", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOMkcxSkRyaW1yS2hpaXdxVVN0YlVwX1Y5bnB1TjJFMVZZckdwMW5JakpGWFhMTVdGSExjSGxzN0ZDb2hXZGxXTTRWeUhlLVQ4bm1xLTFYZkR2SjA0M3drdDBXYjhYMkdZVDRKR05TT08xcVo1b3RndFBpREpQd2hDRDRGaE9hdGVMdy0tQXVXUXBrbU5iYm1fQ1ZSSW9ldFNUaGo0V1RDek9TTzlmZUhfa0tsNEhWRzZUQ2g3U05MUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxOMUJMZUZQemlhV1oxNENzNWRicFl1YVpBVnlTQVJkanF5RDAtM1NFZFh4U3U2dnZiZUVwc09XRWctTVRkd2oxU2hFYUhEVzBsSmxlbTBrd0dpU0psMmNpUzdzd1RlU2V4WGxUeElKSVFLVVFtQjNBdDRxV2k5Uk1vaXdGRGRtSFdmVjdweTB4eUpFMDlJbW55Wk9XUFFYOXRhM2VJNzlBV0pOaW00U3YwbklOUjNHY0s3YTNlLURvbjZwN2RQTzVGUDJfeVItcHR5aWQxcHA5SDlYdk1JVWFWaE9QYU83YnNNSXU5Rk9Ib1U?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics jumps on NDV-01 12-month Phase 2 data and $160M private placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOUE00WER4UWotM3JLNnV3cUFuWDF6Nmk2alVLVUo1R0hxaTZsdXgyQ0plTC04ZVoxWFo2a0JUZExFNUw4a3ZqRHZoeE5CWVFIUVo3cldFYVNoLV81QXRGQlljeTVBcG40ZnhHaUFPclVrYXZZckFSSUxaOWlhb1YwQzFRYmdLcW9wZ09OQi1UX0d5WVY5X05QQVh2VUFNX3lMZVBKMmc2NFdkWXh1cVdkTkhWYnpzTzQ0ZjJNTU1n?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "RELMADA THERAPEUTICS INC (RLMD) Stock Chart", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTFB1bEh5Y2NNbFRFY05zU0pDMFhCVkFHYnU2WWpkZTA5a0RzSlFjVy16clBYeDcxcUxlcVBfc2oxd2RMWVBrcVoxV2xJdVBpUWNXYnpFNjRmSnJGd3o1bmtoSG54a3M?oc=5", "source_name": "ChartMill", "published_at": "2026-07-11T00:00:02+00:00", "published_display": "11 Jul 2026 00:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho Securities Maintains Relmada Therapeutics(RLMD.US) With Buy Rating, Maintains Target Price $19", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPZmdvamZ2VlRHU1h0YWhndWd6VVh5eHNocW45dkxTazNZblJLQi1mWTFQMUlxUXZSTTlUT09lTHRHdnVjdHlPWkFjTnRhdTRqN2pnSVdrT1pCbjMwMmh1Mk9GV0c5NTBpMUYyYWZ5OEdMdGV6WU42YVZ1elRHd1JkMEpDTU9kcHQ1RzBuQ2NEZGxyYkVYZ1ZpX3FLcHppWmttSDZ6dUZBTFZ2YlJCMFVGYzlNZzNuY2pwRHpUUEVyTGQ?oc=5", "source_name": "Moomoo", "published_at": "2026-07-10T12:31:00+00:00", "published_display": "10 Jul 2026 12:31", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics (RLMD) Short Interest & Short Float | Updated Jul 2026", "summary": "Relmada Therapeutics (RLMD) saw a significant increase in short interest, with 10.65 million shares sold short as of June 30, 2026, marking a 75.70% rise from the previous report. The short interest ratio stands at 3.1 days to cover, and 11.87% of the public float is sold short. ", "url": "https://www.marketbeat.com/stocks/NASDAQ/RLMD/short-interest/", "source_name": "MarketBeat", "published_at": "2026-07-10T09:40:39", "published_display": "10 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RLMD - Relmada Therapeutics Inc Options", "summary": "This article provides a detailed financial overview of Relmada Therapeutics Inc (RLMD) options, including its last closing price, market capitalization, various financial ratios, and stock performance metrics. It lists key data points such as EPS, sales growth, insider/institutio", "url": "https://finviz.com/stock?t=RLMD&b=2&p=m&ty=oc&ov=list_strike&s=5", "source_name": "Finviz", "published_at": "2026-07-04T10:10:45", "published_display": "04 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Relmada Therapeutics, Inc. \u2013 NASDAQ:RLMD", "summary": "The article displays the \"Price to book forward\" metric for Relmada Therapeutics, Inc. (NASDAQ: RLMD). It provides the financial data for the company under this specific financial analysis category. The content is presented with a focus on financial information related to the sto", "url": "https://www.tradingview.com/symbols/NASDAQ-RLMD/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T06:40:10", "published_display": "30 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics Joins Russell 2000\u00ae and Russell 3000\u00ae Indexes", "summary": "Relmada Therapeutics, a clinical-stage biotechnology company, announced its inclusion in the Russell 2000\u00ae and Russell 3000\u00ae Indexes, effective after market close on June 26, 2026. This inclusion reflects the company's progress, including robust 12-month data for its NDV-01 candi", "url": "https://finance.yahoo.com/markets/stocks/articles/relmada-therapeutics-joins-russell-2000-110000111.html", "source_name": "Market source", "published_at": "2026-06-30T05:10:23", "published_display": "30 Jun 2026 05:10", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics Joins Russell 2000, Russell 3000 Indexes", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/relmada-therapeutics-joins-russell-2000-185518318.html", "source_name": "MT Newswires", "published_at": "2026-06-29T18:55:18+00:00", "published_display": "29 Jun 2026 18:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics, Inc.(NasdaqCM: RLMD) added to Russell 2500 Growth Benchmark", "summary": "Relmada Therapeutics, Inc. (NasdaqCM: RLMD) has been added to the Russell 2500 Growth Benchmark, reflecting a significant inclusion in key market indices. This follows several other recent inclusions in various Russell indices, including the Russell 2000, Russell 3000, and Russel", "url": "https://www.marketscreener.com/news/relmada-therapeutics-inc-nasdaqcm-rlmd-added-to-russell-2500-growth-benchmark-ce7f5fdfda81f121", "source_name": "marketscreener.com", "published_at": "2026-06-29T19:39:36", "published_display": "29 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada lands in Russell 2000 and Russell 3000 after reconstitution", "summary": "Relmada Therapeutics (Nasdaq: RLMD) announced its inclusion in the Russell 2000 and Russell 3000 indexes, effective after the U.S. market close on June 26, 2026. This addition, part of the Russell Indexes reconstitution, is a significant accomplishment reflecting the company's pr", "url": "https://www.stocktitan.net/news/RLMD/relmada-therapeutics-joins-russell-2000-and-russell-3000-wqppl77notsm.html", "source_name": "Stock Titan", "published_at": "2026-06-29T11:12:40", "published_display": "29 Jun 2026 11:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Relmada Therapeutics, Inc. \u2013 NASDAQ:RLMD", "summary": "The article focuses on the \"Price to earnings forward\" metric for Relmada Therapeutics, Inc. (NASDAQ: RLMD). It appears to be a financial data snippet from TradingView, indicating a specific financial valuation measure for the company. The content itself provides the context of w", "url": "https://www.tradingview.com/symbols/NASDAQ-RLMD/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T10:12:40", "published_display": "29 Jun 2026 10:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics, Inc.(NasdaqCM: RLMD) added to Russell 2500 Index", "summary": "Relmada Therapeutics, Inc. (NasdaqCM:RLMD), a clinical-stage biotechnology company specializing in CNS and metabolic disorders, has been added to the Russell 2500 Index. This inclusion follows several other recent additions to various Russell indexes, including the Russell Small ", "url": "https://www.marketscreener.com/news/relmada-therapeutics-inc-nasdaqcm-rlmd-added-to-russell-2500-index-ce7f5fdfd188f324?utm_source=copy&utm_medium=social&utm_campaign=share", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T05:10:23", "published_display": "29 Jun 2026 05:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RLMD: Next-Generation Bladder Cancer Therapy Platform Will Drive Future Upside Potential", "summary": "The fair value estimate for Relmada Therapeutics (RLMD) has increased to $12.67, driven by a new analyst target and the perceived differentiation of its NDV-01 platform for bladder cancer therapy. The company has also increased its authorized common stock and was added to the S&P", "url": "https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-rlmd/relmada-therapeutics/ksrf7qxl-bladder-cancer-and-compulsive-disorder-therapies-will-support-a-stronger-long-term-outlook/updates/2-the-analyst-price-target-for-relmada-therapeutics-has-shifte", "source_name": "Simply Wall Street", "published_at": "2026-06-27T04:09:30", "published_display": "27 Jun 2026 04:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RLMD Jumps As HC Wainwright Launches Buy Coverage", "summary": "Relmada Therapeutics Inc. (RLMD) saw its stock jump by 3.72% after H.C. Wainwright initiated coverage with a Buy rating and a $12 price target, driven by optimism for its NDV-01 clinical trial. Despite current negative earnings and heavy R&D burn, the company maintains a strong b", "url": "https://www.timothysykes.com/news/relmadatherapeuticsinc-rlmd-news-2026_06_26-2/", "source_name": "Timothy Sykes", "published_at": "2026-06-26T20:38:00", "published_display": "26 Jun 2026 20:38", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics Inc Actuals & Estimates (NASDAQ:RLMD)", "summary": "This article provides an overview of Relmada Therapeutics, Inc. (NASDAQ: RLMD) stock, including its current price, market capitalization, and analyst forecasts. It details historical performance, future earnings estimates, and answers frequently asked questions regarding its fina", "url": "https://www.tradingview.com/symbols/NASDAQ-RLMD/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:40:35", "published_display": "26 Jun 2026 07:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RLMD Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "Relmada Therapeutics, Inc. (RLMD) has a one-year price target of $12.67 based on 6 analyst forecasts. Analysts predict a maximum price of $19.00 and a minimum of $9.00 for RLMD. The company's stock has seen a significant increase of 1190% over the last year, despite recent weekly", "url": "https://www.tradingview.com/symbols/NASDAQ-RLMD/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T05:39:55", "published_display": "26 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Millennium Group reports 4.57M Relmada shares (NASDAQ: RLMD) in 13G", "summary": "Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have reported shared voting and dispositive power over 4,567,952 shares of Relmada Therapeutics (NASDAQ: RLMD), representing 4.4% of the common stock. This Schedule 13G filing indicates that the r", "url": "https://www.stocktitan.net/sec-filings/RLMD/schedule-13g-relmada-therapeutics-inc-passive-investment-disclosure-5-c17743bef71e.html", "source_name": "Stock Titan", "published_at": "2026-06-23T21:10:21", "published_display": "23 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics stock maintained at Buy by H.C. Wainwright", "summary": "H.C. Wainwright has reiterated a Buy rating and a $12.00 price target for Relmada Therapeutics Inc (NASDAQ:RLMD), highlighting the company's strong financial position and promising clinical pipeline for its NDV-01 program. Despite a recent net loss that slightly missed analyst fo", "url": "https://www.investing.com/news/analyst-ratings/relmada-therapeutics-stock-maintained-at-buy-by-hc-wainwright-93CH-4755239", "source_name": "Investing.com", "published_at": "2026-06-23T12:12:14", "published_display": "23 Jun 2026 12:12", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains Relmada Therapeutics(RLMD.US) With Buy Rating, Maintains Target Price $12", "summary": "H.C. Wainwright has reaffirmed its Buy rating for Relmada Therapeutics (RLMD.US) and maintained its target price of $12. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/71891923/hc-wainwright-maintains-relmada-therapeutics-rlmdus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-23T11:40:10", "published_display": "23 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Reiterates Buy Rating on Relmada Therapeutics Inc (RLMD)", "summary": "H.C. Wainwright analyst Andres Maldonado has reiterated a Buy rating on Relmada Therapeutics Inc (RLMD) with a $12.00 price target. The article, published on June 23, 2026, is a premium content piece and requires a subscription to StreetInsider.com for full access.", "url": "https://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Relmada+Therapeutics+Inc+%28RLMD%29/26675565.html", "source_name": "StreetInsider", "published_at": "2026-06-23T11:12:14", "published_display": "23 Jun 2026 11:12", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13G Relmada Therapeutics For: 22 June By Investing.com", "summary": "This article reports on a Form 13G filing for Relmada Therapeutics, dated June 22. It mentions the stock symbol RLMD and includes minor fluctuations in various global indices and commodities. The primary content of the article is the announcement of the Form 13G filing itself, wi", "url": "https://ng.investing.com/news/stock-market-news/form-13g-relmada-therapeutics-for-22-june-93CH-2568939", "source_name": "Investing.com Nigeria", "published_at": "2026-06-23T01:40:10", "published_display": "23 Jun 2026 01:40", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics, Inc.(NasdaqCM:RLMD) added to S&P Pharmaceuticals Select Industry Index", "summary": "Relmada Therapeutics, Inc. (NasdaqCM:RLMD) has been added to the S&P Pharmaceuticals Select Industry Index. The company is a clinical-stage biotechnology firm focused on developing therapies for central nervous system (CNS) and metabolic disorders, with its lead product candidate", "url": "https://www.marketscreener.com/news/relmada-therapeutics-inc-nasdaqcm-rlmd-added-to-s-p-pharmaceuticals-select-industry-index-ce7f5cd3d88df72c", "source_name": "marketscreener.com", "published_at": "2026-06-22T13:09:50", "published_display": "22 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 78, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics Inc (RLMD) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Relmada Therapeutics Inc (RLMD), noting its current risk score of 1.94, ranking 255 out of 389 in the Biotechnology & Medical Research industry. The company's beta is 0.40, indicating lower volatility relative to the S&P 500. The assess", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rlmd/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-19T08:39:59", "published_display": "19 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics (RLMD): 10 Best Growth Stocks Under $30 to Buy Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOc2lmUHFjQlhWTmVtRDZaVnJaVkViU2tzTEtPcmp5c1ZDdUJxTk8yOTZlZ0VPYUhPdTdqeVRkMFlBUndwQkhqczRzeGFYc2JaZXoyQ3pWUWF5Sm9RdTZwX0JTMWlzOWo2QmdWZ0cyckFsTGJZVVdHQzlhcWp0SmpXWW5qQ0o1UFY0UngtYmtrY3VsamEwblNNa0hB?oc=5", "source_name": "Market source", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada: NDV-01 Entering Phase 3 In NMIBC, But There's No Rush To Buy Stock Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWk0tUnBlNzAyVGdYRW1mMmRnMENaTEZQeVpwcnZFVFdackRzQWI0bkhFVno0S3ZSZnVsSVZmYVo5bHQzT3dZaTBIY3pCdE0yRHZ6VVdlczBMQUtITHBQeXJpLWstdVJhbEkwbHVKamt0SkcteXljcVZmYzFVd2ZveENBVjJQOTk2VG1PU0ZCczBOa1ZEUlVPeVFtd1R3UGR1b3lTVEd0Z3NETEJN?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RLMD News | RELMADA THERAPEUTICS INC (NASDAQ:RLMD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTE5oWENYWllaMVNjSTJqTjNMNzIwdHVIVktVMjZJcmo4VHBRa0w3aFJpWEZQa0hSOVpNV1BvTDdmdHNBZ0RsWlBNTURhSHBiSU1TRXhWaklHRjhRcEk?oc=5", "source_name": "ChartMill", "published_at": "2026-06-19T00:27:17+00:00", "published_display": "19 Jun 2026 00:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Initiates Relmada Therapeutics(RLMD.US) With Buy Rating, Announces Target Price $12", "summary": "H.C. Wainwright has initiated coverage on Relmada Therapeutics (RLMD.US) with a Buy rating. The firm has set a target price of $12 for the company's stock.", "url": "https://www.moomoo.com/news/post/71726864/hc-wainwright-initiates-relmada-therapeutics-rlmdus-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-06-19T00:40:23", "published_display": "19 Jun 2026 00:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HC Wainwright Initiates Relmada Therapeutics at Buy With $12 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/hc-wainwright-initiates-relmada-therapeutics-104623782.html", "source_name": "MT Newswires", "published_at": "2026-06-18T10:46:23+00:00", "published_display": "18 Jun 2026 10:46", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RLMD Initiates Coverage On by HC Wainwright & Co. -- Rating Set to Buy", "summary": "HC Wainwright & Co. initiated coverage on Relmada Therapeutics (RLMD) with a 'Buy' rating and a $12.00 target price. Despite a low GF Score\u2122 of 30/100 due to profitability and growth concerns, the company exhibits strong financial health. Analysts are confident in RLMD's potentia", "url": "https://www.gurufocus.com/news/8922324/rlmd-initiates-coverage-on-by-hc-wainwright-co-rating-set-to-buy", "source_name": "GuruFocus", "published_at": "2026-06-18T11:39:34", "published_display": "18 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright initiates Relmada stock coverage with buy rating", "summary": "H.C. Wainwright has initiated coverage on Relmada Therapeutics Inc (NASDAQ:RLMD) with a Buy rating and a $12 price target, citing its promising NDV-01 for non-muscle invasive bladder cancer. The stock has seen an impressive 843% one-year return, despite the company currently bein", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-initiates-relmada-stock-coverage-with-buy-rating-93CH-4749423", "source_name": "Investing.com", "published_at": "2026-06-18T11:08:09", "published_display": "18 Jun 2026 11:08", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Starts Relmada Therapeutics Inc (RLMD) at Buy, PT $12", "summary": "H.C. Wainwright analyst Andres Maldonado has initiated coverage on Relmada Therapeutics Inc (NASDAQ: RLMD) with a Buy rating. The firm has set a price target of $12 for the stock. This news indicates a positive outlook from H.C. Wainwright on the pharmaceutical company.", "url": "https://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Starts+Relmada+Therapeutics+Inc+%28RLMD%29+at+Buy%2C+PT+%2412/26662122.html", "source_name": "StreetInsider", "published_at": "2026-06-18T05:59:00", "published_display": "18 Jun 2026 05:59", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics Inc (RLMD) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Relmada Therapeutics Inc (RLMD), identifying its major shareholders and institutional holdings. It provides a breakdown of shareholder types, institutional shareholding trends over several quarters, and recent shareholder activity", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rlmd/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T21:09:45", "published_display": "17 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics Inc (RLMD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey focuses on the revenue breakdown of Relmada Therapeutics Inc (RLMD). It notes that relevant data regarding the company's business segments, regional revenue, and profit contribution have not yet been disclosed by Relmada Therapeutics Inc. The page pri", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rlmd/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T20:09:44", "published_display": "17 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10 Best Growth Stocks Under $30 to Buy Now", "summary": "This article identifies Relmada Therapeutics Inc. (NASDAQ:RLMD) as one of the best growth stocks under $30, highlighting its strong financial position and promising clinical pipeline. The company recently reported positive Phase 2 data for NDV-01, is well-capitalized to fund oper", "url": "https://www.insidermonkey.com/blog/10-best-growth-stocks-under-30-to-buy-now-1782530/4/", "source_name": "Insider Monkey", "published_at": "2026-06-17T11:19:09", "published_display": "17 Jun 2026 11:19", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics Inc (RLMD) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Relmada Therapeutics Inc (RLMD), noting its current valuation score of 7.88 within the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -6.02 and indicates that relevant data for P/B, P/S, and P/CF r", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rlmd/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-16T23:39:34", "published_display": "16 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics Inc (RLMD) Institutional Confidence", "summary": "Relmada Therapeutics Inc (RLMD) has an institutional shareholding score of 5.00, placing it 133rd in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 56.47%, a significant quarter-over-quarter increase of 184.86%. Steven Cohen is ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rlmd/sentiment", "source_name": "TradingKey", "published_at": "2026-06-15T22:39:58", "published_display": "15 Jun 2026 22:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics bolsters Sepranolone Program with Michael Quirk as Senior Advisor", "summary": "Relmada Therapeutics has appointed Michael Quirk as Senior Advisor for its Sepranolone Program, aiming to advance its central nervous system drug development. Dr. Quirk, a neuroscience veteran from Sage Therapeutics and AstraZeneca, brings over 20 years of experience in CNS trans", "url": "https://www.indianpharmapost.com/people/relmada-therapeutics-bolsters-sepranolone-program-with-michael-quirk-as-senior-advisor-20596", "source_name": "Indian Pharma Post", "published_at": "2026-06-13T08:38:57", "published_display": "13 Jun 2026 08:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/relmada-therapeutics-appoints-cns-drug-110000301.html", "source_name": "GlobeNewswire", "published_at": "2026-06-11T11:00:00+00:00", "published_display": "11 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/relmada-therapeutics-present-jefferies-global-110000984.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T11:00:00+00:00", "published_display": "28 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics Inc (RLMD) Q1 2026 Earnings Call Highlights: Strong Financial Position and ...", "summary": "", "url": "https://finance.yahoo.com/news/relmada-therapeutics-inc-rlmd-q1-050201950.html", "source_name": "GuruFocus.com", "published_at": "2026-05-13T05:02:01+00:00", "published_display": "13 May 2026 05:02", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics Q1 Loss per Share Narrows", "summary": "", "url": "https://finance.yahoo.com/news/relmada-therapeutics-q1-loss-per-203559813.html", "source_name": "MT Newswires", "published_at": "2026-05-12T20:35:59+00:00", "published_display": "12 May 2026 20:35", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPWVFQZXhLNzNORGl4ZFdtc0xxd0pnekFYemIydldWc21EUWFrVFExX2FzYy1wVkY2V1ZPa2tlQVoxcFNCVEVLOFJLRmRjdHp2U1lVeDV5ZkFrXzlUVUxpMkFsUXB0VDlRX19kTWR1Ujc4LWVzQjBMNlJJMnNXLW0yVXhkTjdjT0lad0pMdFZUbGUyM0hpVFg3Nk83SkpsRU94NkZZTmw4SFVEdGZxS3c?oc=5", "source_name": "TradingView", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxPNDREOVlWclVTeUYtREpEcTUzTzNlMGkwRlhrbzBvTjA3QTN4TnZHN1UyODFZUFdCTUh6Yk5rTFFYNTFWR2Z4TDhXTnFrenN2WXFmNUxaR3JoZFZSNlIzazVGcEtLZVVWdHZiM2d0cEo5eDlnZmJFTEVKR0MtVldwRVlxVXVHc1YzOXlKeUNYRWtsTXFpaHR4M1BVX3ZITGk4Z1hCRzJyMmJOZDFBVnRwYWZjZ1p3SDYxYi0tZENncnBua2lOcDJrVmt1cXQtMWluTmdhQ1puZHVUdjhNNjVQQkt6OTlZLVpKeHNiS3FSMlIyMDBMVzlrUzVn?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Relmada will discuss Q1 results and business update May 12", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOOTJRQVpnVjV2WlMxdkxpQ19XNmFLd0hWWUk2TTRxenhnNXRqWnptdGNhNGxyZklobmdrU0RSbHZjbnBjWGxEaW1PNVlnZ3A5WUUtRnVWaDBsamFmbGhPZ1lva1Y5VzN2dHFQcDgzNnFRS1pZcXdPNEJfbG5uWVNXX1FPRkwtM3JmenN0OUxJelFNTkRhSjh0aE5ZMklNcHhBTmNyeDdJSkV1NlAwanBPN0JrcWhwZDR1eGNkMUNWQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Relmada Therapeutics (RLMD) Have the Potential to Rally 75.58% as Wall Street Analysts Expect?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNYWdLdG5pQUtrQW1mUHF1ODRSWFJTS2JTOTNxU0NveGtvM2drazdxYTJHcDBoanVKUTlGeTRYOE5vTWFHUVBLSjVzWU5qWEx2a1R1Ykc1N2JNMVFJdEpjYkJtRklQLTlDUXVIejJCWDd3SldPWTgtcFpRbkdYUy13TkpDUi0wVDFIVXF4ZGZBRlNJSG41Y3hkMWNKV2E4Q0NwejkxNDB5Qk42UURaYTg4?oc=5", "source_name": "qz.com", "published_at": "2026-04-22T22:35:53+00:00", "published_display": "22 Apr 2026 22:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAJBVV95cUxObmp0dXNWNW9Ub2lLMkEyUWpvbzJQMzhMRGhyV1lMb281clFDa0FZcXBKSEk4d01qcmY4QVdZV3gyNEd1RFNPR204eVJWeFBTeEVmNjg2MG1NMzlKV2JINmltWGhGM0RXSVV1czhDVWtZNXhlRmZZZTBIVVZGTGdkZktYdHdkZWlHalFjc1g1OFYySUJIcnNyeGktbG9tMWJ1V1k2NnZBV1VDbVZMNkhLa0VidTQxZEFLUXJmdUdLc3hvdkFjcmtGN19Oa3pqMmY1aEZvOXhQSzZvUnRNbmJpMUZOM3FYZjd0TXAtNzBBVFVfLVlZMUoxbzVGOHFGVE81S2t2bENhRHlQbzNZdDNZd2dLWFZKN1EtczBlYnZCX291VjdTbG9GVTJ1LTY?oc=5", "source_name": "TradingView", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics: 2 New Assets, 2 New 'Blockbusters'? I'd Wait And See (NASDAQ:RLMD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPdHhNY2FMMjd6dGpyb2M1Q0kyMkgtOXhFYkNWQ1M4ZVhfVlpmY2sxcHh3V2NLcU1wZ21Pci1xUVo5Sm1qc1dhTGs0SllUejRqcDJuS3JzTG5OMFlGV2g5WjZTUThmMWtmblJMV2lrQl9vX2JEUmlhVnRkSVE0UHZvenUzM3A3OHRkYzNhRDBRN2VzQk95aHh3eEU2alBOci1rbWIyN3ZPVmdpa25tNGc?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s What Makes Mizuho Bullish on Relmada Therapeutics Inc (RLMD) Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQbEYtWlY0RnkzbE5rbjEzNTlXRS0tZUs3Y2twWlljYy16RGw5OFpnLWFDU0lKWHhmamZqN0d6aDRKWUN2UWd4VHFZU0lqZHdFUEdDWTMyc0VheHo2VnliTjVfNXktQVo0THBDTUNmQkdya1dOeVlURHJ3d1BWWXIyblBlUHRfWVBxTXdHY0VPclRNTnZ1dmExZUJleVB6WkZJWG80VVhXR1hfQQ?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada wins bullish view at Piper Sandler on cancer therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxNLWR5WmFILUtTTVVOaWJMc19zQjFOWW5KZVp2T0R5Wm5VSzltaVFnbjRNbmtYM083N0JkckdoRHdrS0hBZ0xZSWxmZ1lrdlVja1NMNk01Q2Y4dGF5SGRHaUd4MERsRkRjX0tUSUF2TFRHM1g2QUZWQ0ZsYlFBdnZnZVZTcTQ5bEpoeHJN?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Relmada Therapeutics (RLMD) Valuation After NDV\u201101 Phase 2 Bladder Cancer Data", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Relmada secures $160M private raise for drug R&D and operations", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOMkcxSkRyaW1yS2hpaXdxVVN0YlVwX1Y5bnB1TjJFMVZZckdwMW5JakpGWFhMTVdGSExjSGxzN0ZDb2hXZGxXTTRWeUhlLVQ4bm1xLTFYZkR2SjA0M3drdDBXYjhYMkdZVDRKR05TT08xcVo1b3RndFBpREpQd2hDRDRGaE9hdGVMdy0tQXVXUXBrbU5iYm1fQ1ZSSW9ldFNUaGo0V1RDek9TTzlmZUhfa0tsNEhWRzZUQ2g3U05MUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxOMUJMZUZQemlhV1oxNENzNWRicFl1YVpBVnlTQVJkanF5RDAtM1NFZFh4U3U2dnZiZUVwc09XRWctTVRkd2oxU2hFYUhEVzBsSmxlbTBrd0dpU0psMmNpUzdzd1RlU2V4WGxUeElKSVFLVVFtQjNBdDRxV2k5Uk1vaXdGRGRtSFdmVjdweTB4eUpFMDlJbW55Wk9XUFFYOXRhM2VJNzlBV0pOaW00U3YwbklOUjNHY0s3YTNlLURvbjZwN2RQTzVGUDJfeVItcHR5aWQxcHA5SDlYdk1JVWFWaE9QYU83YnNNSXU5Rk9Ib1U?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relmada Therapeutics jumps on NDV-01 12-month Phase 2 data and $160M private placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOUE00WER4UWotM3JLNnV3cUFuWDF6Nmk2alVLVUo1R0hxaTZsdXgyQ0plTC04ZVoxWFo2a0JUZExFNUw4a3ZqRHZoeE5CWVFIUVo3cldFYVNoLV81QXRGQlljeTVBcG40ZnhHaUFPclVrYXZZckFSSUxaOWlhb1YwQzFRYmdLcW9wZ09OQi1UX0d5WVY5X05QQVh2VUFNX3lMZVBKMmc2NFdkWXh1cVdkTkhWYnpzTzQ0ZjJNTU1n?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 102, "total_relevant": 64, "sentiment_summary": {"positive": 25, "negative": 4, "neutral": 35, "score": 58, "total": 64, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 20.3, "count": 35}, {"event": "earnings", "label": "Earnings", "weight": 7.7, "count": 16}, {"event": "analyst", "label": "Analyst action", "weight": 6.6, "count": 12}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 25, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 6.41, "latest_week": "2026-07-10", "one_week_move": 2.1, "four_week_move": -3.6, "twelve_week_move": -14.3, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.598393, "market_dynamics_buy_signal": false, "relative_strength": 35.192671, "fair_value_gap": 106.8, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 54.1914, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+2.1% over one week, -3.6% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 68, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 8}, {"label": "TradingView", "count": 7}, {"label": "TradingKey", "count": 5}, {"label": "Stock Titan", "count": 4}, {"label": "GlobeNewswire", "count": 4}, {"label": "Moomoo", "count": 3}, {"label": "MT Newswires", "count": 3}, {"label": "Seeking Alpha", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 56}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 35}, {"label": "Earnings", "count": 16}, {"label": "Analyst action", "count": 12}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "56", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+2.1% over one week, -3.6% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "RELMADA THERAPEUTICS INC (RLMD) Stock Chart"}], "updated_at": "2026-07-16T00:45:36.690482+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}